Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors

GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion...

15 February, 2023

New GMP cell encapsulation device : interview of COO Michael Lanero Fidalgo

We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACR™ technology and her interest in TreeFrog's...

28 October, 2022

3 PhD students from King’s College London win the $100,000 Stem Cell SpaceShot grant

Bordeaux, France, Cambridge (MA), USA / October 20th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced that an international team composed of 3 PhD students from King’s College...

20 October, 2022

TreeFrog Therapeutics moves to GMP manufacturing with cell encapsulation device delivered by Invetech

The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support...

11 October, 2022

10 International Scientists Nominated For The $100,000 Stem Cell SpaceShot Grant

Bordeaux, France / August 30th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the nomination of 10 international scientists for the Stem Cell SpaceShot grant. Each...

30 August, 2022

Peter Nell joins TreeFrog Therapeutics as Independent Board Member

Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell & gene therapy field over the past ten years and is currently building a new...

25 July, 2022

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France / June 10th, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf,...

10 June, 2022

TreeFrog Therapeutics launches a $100,000 research grant in regenerative medicine

Bordeaux, France / April 19th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in...

19 April, 2022

TreeFrog Therapeutics expands Board with new independent members from the cell therapy industry

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and...

14 April, 2022

TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and...

08 April, 2022